Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 2018297

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2018297

Dasatinib Market Size, Share & Trends Analysis Report By Drug Type, (Branded, Generic), By Indication (Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL)), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Dasatinib Market Summary

The global dasatinib market size was estimated at USD 5.59 billion in 2025 and is projected to reach USD 7.57 billion by 2033, growing at a CAGR of 4.27% from 2026 to 2033. The global dasatinib market is expanding due to the rising prevalence of hematologic malignancies, particularly chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.

Increasing awareness of targeted oncology therapies has improved diagnosis and early treatment initiation across developed and emerging regions. Physicians prefer tyrosine kinase inhibitors for sustained disease control, supporting long term demand. Longer survival has increased cumulative drug utilization, strengthening revenue visibility. For instance, November 2025, OncLive reported FDA approval of a generic dasatinib abbreviated new drug application in six strengths, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. Initial clearance occurred in 2006, with expansion in January 2019 based on a phase 2 trial in 78 pediatric patients showing 64.1 percent 3 year event free survival, 95 percent confidence interval 52.4 percent to 74.7 percent, 96 percent below 5 percent marrow blasts at induction, 97 percent at consolidation, 4 percent fatal adverse effects among 81 patients, and 10 percent discontinuation.

Advancements in precision medicine and molecular diagnostics have strengthened biomarker driven therapy selection, accelerating adoption of targeted treatments such as dasatinib. Clinical evidence in resistant or intolerant chronic myeloid leukemia has reinforced physician confidence and supported guideline recommendations for second generation tyrosine kinase inhibitors. For instance, January 2026, Cancer Reports published a retrospective analysis of 53 adults treated with low dose dasatinib 50 mg daily between 2002 and 2025, with a median age of 50 years. Molecular response outcomes included 41.5 percent achieving MR4.5, 20.8 percent MR4.0, and 15.1 percent major molecular response without deep response. Tyrosine kinase domain mutations were present in 32.1 percent, clinically significant adverse events in 49.1 percent, 22.6 percent required switching for inadequate response, and 7.5 percent for intolerance. Baseline BCR ABL1 greater than or equal to 100 percent, T315I mutation, and high ELTS risk predicted poorer outcomes.

Global Dasatinib Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dasatinib market report based on drug type, indication, distribution channel, and region:

  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generic
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Chronic Myeloid Leukemia (CML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Oncology Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68040-865-7

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Type
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Dasatinib Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Dasatinib Market: Drug Type Business Analysis

  • 4.1. Drug Type Market Share, 2025 & 2033
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2021 - 2033 (USD Million)
  • 4.5. Generic
    • 4.5.1. Generic Market, 2021 - 2033 (USD Million)

Chapter 5. Dasatinib Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 5.4. Chronic Myeloid Leukemia (CML)
    • 5.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
  • 5.5. Acute Lymphoblastic Leukemia (ALL)
    • 5.5.1. Acute Lymphoblastic Leukemia (ALL) Market, 2021 - 2033 (USD Million)

Chapter 6. Dasatinib Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.7. Specialty Oncology Pharmacies
    • 6.7.1. Specialty Oncology Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Dasatinib Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Dasatinib Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Bristol-Myers Squibb Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Teva Pharmaceutical Industries Ltd.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sandoz Group AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Sun Pharmaceutical Industries Limited
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Hetero Drugs Limited
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Aurobindo Pharma Limited
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Dr. Reddy's Laboratories Limited
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Intas Pharmaceuticals Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Cipla Limited
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Lupin Limited
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-865-7

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global dasatinib market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 5 Global dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 6 Global dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 9 North America dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 10 North America dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 12 U.S. dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 13 U.S. dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 15 Canada dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 16 Canada dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 18 Mexico dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 19 Mexico dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 22 Europe dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 23 Europe dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 25 UK dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 26 UK dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 28 Germany dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 29 Germany dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 31 France dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 32 France dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 34 Italy dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 35 Italy dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 37 Spain dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 38 Spain dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 40 Norway dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 41 Norway dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 43 Denmark dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 44 Denmark dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 46 Sweden dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 47 Sweden dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 53 Japan dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 54 Japan dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 56 China dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 57 China dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 59 India dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 60 India dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 62 Australia dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 63 Australia dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 65 South Korea dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 66 South Korea dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 68 Thailand dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 69 Thailand dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 72 Latin America dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 73 Latin America dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 75 Brazil dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 76 Brazil dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 78 Argentina dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 79 Argentina dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 85 South Africa dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 86 South Africa dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 91 UAE dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 92 UAE dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 95 Kuwait dasatinib market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Dasatinib market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Dasatinib market dynamics
  • Fig. 11 Dasatinib market: Porter's five forces analysis
  • Fig. 12 Dasatinib market: PESTLE analysis
  • Fig. 13 Drug type market, 2021 - 2033 (USD Million)
  • Fig. 14 Branded market, 2021 - 2033 (USD Million)
  • Fig. 15 Generic market, 2021 - 2033 (USD Million)
  • Fig. 16 Indication market, 2021 - 2033 (USD Million)
  • Fig. 17 Chronic Myeloid Leukemia (CML) market, 2021 - 2033 (USD Million)
  • Fig. 18 Acute Lymphoblastic Leukemia (ALL) market, 2021 - 2033 (USD Million)
  • Fig. 19 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 20 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 21 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Specialty oncology pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Dasatinib market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 50 Asia Pacific Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 63 Latin America Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 68 MEA Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!